Zacks: NuCana PLC Sponsored ADR (NCNA) Given Consensus Recommendation of “Strong Buy” by Analysts

NuCana PLC Sponsored ADR (NASDAQ:NCNA) has received a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy recommendation.

Brokerages have set a twelve-month consensus price objective of $24.00 for the company, according to Zacks. Zacks has also assigned NuCana PLC Sponsored ADR an industry rank of 104 out of 265 based on the ratings given to related companies.

A number of research firms recently commented on NCNA. Jefferies Group LLC began coverage on NuCana PLC Sponsored ADR in a report on Monday. They issued a “buy” rating and a $25.00 price target on the stock. William Blair began coverage on NuCana PLC Sponsored ADR in a report on Monday. They issued an “outperform” rating on the stock. Citigroup Inc. began coverage on NuCana PLC Sponsored ADR in a report on Monday. They issued a “buy” rating and a $23.00 price target on the stock. Finally, Cowen and Company began coverage on NuCana PLC Sponsored ADR in a report on Monday. They issued an “outperform” rating on the stock.

Shares of NuCana PLC Sponsored ADR (NCNA) remained flat at $12.50 during midday trading on Friday. The stock had a trading volume of 101,075 shares. The company’s market cap is $397.64 million. The company has a 50-day moving average price of $15.68 and a 200 day moving average price of $15.68. NuCana PLC Sponsored ADR has a 12 month low of $11.74 and a 12 month high of $19.95.

TRADEMARK VIOLATION NOTICE: “Zacks: NuCana PLC Sponsored ADR (NCNA) Given Consensus Recommendation of “Strong Buy” by Analysts” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/zacks-nucana-plc-sponsored-adr-ncna-given-consensus-recommendation-of-strong-buy-by-analysts.html.

NuCana PLC Sponsored ADR Company Profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Get a free copy of the Zacks research report on NuCana PLC Sponsored ADR (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NuCana PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply